Skip to main content
Fig. 4 | BMC Cancer

Fig. 4

From: Over-expressing Akt in T cells to resist tumor immunosuppression and increase anti-tumor activity

Fig. 4

Engineer human peripheral blood lymphocytes (PBLs) to target prostate cancer cells. a Immunosuppressive phenotypes of human prostate cancer cell line PC3M were examined by staining with HLA-DR, CD80, B7-H1, TGF-β, and IL-10. b Different constructs used to transduce PBLs, VH, anti-human EpCAM immunoglobulin heavy chain variable region; VL, anti-human EpCAM immunoglobulin light chain variable region; CD28, part of the extracellular domain and the entire transmembrane and intracellular domains of CD28; CD3ζ, the cytoplasmic domain of CD3ζ; IRES, internal ribosome entry sequence. c Human PBLs were transduced with retroviruses encoding EpCAM specific CAR, CAR-Akt, or CAR-myr-Akt, at 5 days after transduction, the mRNA levels of transduced CAR were determined by RT-PCR and real-time PCR, and the protein levels of Akt, phosphorylated Akt were determined by western blot

Back to article page